Evidence map›Paper›PMID 32124075›Full record

ArticleActa diabetologica2020

Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients.

David Azoulay, Sean Abed, Akram Sfadi, Ortal Sheleg, Ety Shaoul, Mona Shehadeh, Edward Kaykov, Marina Nodelman, Amir Bashkin

Abstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Disruption of BDNF signalling in neuropathologies.Biochemical Society transactions · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

David AzoulayHematology Unit and Laboratories, Galilee Medical Center, P.O. Box 21, 22100, Naharia, Israel. davidA@GMC.gov.il.ORCID http://orcid.org/0000-0002-3451-5737
Sean AbedDepartment of Geriatric Medicine, Galilee Medical Center, Naharia, Israel.
Akram SfadiDepartment of Neurology, Galilee Medical Center, Naharia, Israel.
Ortal ShelegHematology Unit and Laboratories, Galilee Medical Center, P.O. Box 21, 22100, Naharia, Israel.
Ety ShaoulHematology Unit and Laboratories, Galilee Medical Center, P.O. Box 21, 22100, Naharia, Israel.
Mona ShehadehAzrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Edward KaykovDepartment of Geriatric Medicine, Galilee Medical Center, Naharia, Israel.
Marina NodelmanDiabetes, Endocrinology and Metabolism Unit, Galilee Medical Center, Naharia, Israel.
Amir BashkinAzrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Western Galilee Hospital · ILBar-Ilan University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies by our group demonstrated brain-derived neurotrophic factor (BDNF) levels in blood and BDNF-Val66met-SNP as potential biomarkers in chemotherapy-induced peripheral neuropathy. Here, we evaluate symptoms of peripheral neuropathy (PN) and depression in patients with type II diabetes mellitus in search of an association with serum BDNF levels and the Val66Met-SNP.

methodsIn total, 90 patients enrolled in the study; 23 (25.6%) had known PN, as determined by nerve conduction studies (NCS-PN), and 67 (74.4%) were not diagnosed with PN (U-PN). PN symptoms were assessed and graded in these groups using the total neuropathy score (TNSr) and DN4 scales. Small nerve fiber testing of sensitivity thresholds to cold, warm and hot pain signals was performed using the Q-sense device. Depression was assessed using the PHQ9 questionnaire. BDNF protein levels and Val66Met-SNP were determined with ELISA and Sanger sequencing, respectively.

resultsNCS-PN patients showed lower serum BDNF levels alongside significantly higher TNSr, DN4 and PHQ9 scores and lower hot pain sensitivity thresholds as compared to U-PN patients. Patients with Met-BDNF-SNP showed increased TNSr scores and lower hot pain sensitivity thresholds as compared to patients with Val-BDNF-SNP. Depression showed a weaker correlation with sensitivity thresholds to hot pain signals as compared to TNSr and DN4 scores.

conclusionsDiminished peripheral BDNF resources and Met-BDNF-SNP genotype are associated with augmented symptoms of PN in patients with type II diabetes mellitus. Sensitivity thresholds to hot pain signals may be less influenced by depression and possibly more accurately detect PN symptoms in diabetic patients.

Indexed as

Polymorphism, Single NucleotideAdultAgedAmino Acid SubstitutionBiomarkersBrain-Derived Neurotrophic FactorCase-Control StudiesDiabetes Mellitus, Type 2Diabetic NeuropathiesFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMethionineMiddle AgedBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorMethionineValineBrain-derived neurotrophic factor (BDNF)Peripheral neuropathy (PN)Val66Met-SNP

Identifiers

PMID32124075
OpenAlexW3009778326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.